Document Detail

Heart failure and pulmonary hypertension.
MedLine Citation:
PMID:  20347789     Owner:  NLM     Status:  MEDLINE    
When pulmonary hypertension (PH) and right ventricular dysfunction accompany heart failure, the impact on functional capacity and prognosis are ominous. Newer clinical strategies to preferentially lower pulmonary pressures and pulmonary vascular tone improve functional performance and symptoms of heart failure by targeting the nitric oxide signal transduction pathways, as with PDE5 inhibition. Additional studies are needed to determine if these therapies will impact long-term patient outcomes and elucidate the specific mechanisms whereby these treatments are effective. Furthermore, the recent finding that mutations in BMPR2 cause familial forms of pulmonary arterial hypertension and that BMPR2 expression is decreased in secondary forms of PH strongly implicate BMP signaling in the underlying pathophysiology of PH. Translation of emerging basic science insights in the vascular biology of PH and BMP signaling will provide novel therapeutic strategies for the spectrum of pulmonary hypertensive diseases.
Jordan T Shin; Marc J Semigran
Related Documents :
20347789 - Heart failure and pulmonary hypertension.
8083939 - Estimation of pulmonary artery pressure in patients with primary pulmonary hypertension...
20956169 - Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
3615869 - Pulmonary arterial hypertension: value of perfusion scintigraphy.
3033179 - Effect of converting enzyme inhibitors on hypertensive large arteries in humans.
17102939 - The protective effect of hmg-coa reductase inhibitors against monocrotaline-induced pul...
19329919 - A look into the endovascular crystal ball.
9696089 - The pathogenesis of arteriovenous malformations: insights provided by a case of multipl...
8077819 - Anatomical and radiological evaluation of the triangular fibrocartilage complex of the ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Heart failure clinics     Volume:  6     ISSN:  1551-7136     ISO Abbreviation:  Heart Fail Clin     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-29     Completed Date:  2010-07-23     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  101231934     Medline TA:  Heart Fail Clin     Country:  United States    
Other Details:
Languages:  eng     Pagination:  215-22     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2010 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Morphogenetic Protein Receptors, Type II / genetics
Cyclic Nucleotide Phosphodiesterases, Type 5 / genetics
Heart Failure / complications,  genetics*,  physiopathology
Hypertension, Pulmonary / complications,  diagnosis,  genetics*,  physiopathology
Nitric Oxide
Phosphodiesterase 5 Inhibitors
Signal Transduction
Ventricular Dysfunction, Right / complications,  genetics*,  physiopathology
Grant Support
Reg. No./Substance:
0/Phosphodiesterase 5 Inhibitors; 31C4KY9ESH/Nitric Oxide; EC protein, human; EC Morphogenetic Protein Receptors, Type II; EC Nucleotide Phosphodiesterases, Type 5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The Genetics of Conduction Disease.
Next Document:  The genetics of congestive heart failure.